Table 1. Innovative Medicines Initiative projects. The first call for 18 projects as part of the Innovative Medicines Initiative (IMI) was recently released. The projects for the initiative, which was jointly established by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), are listed below, with each program's expected contributions from EFPIA and IMI. Of the 24 participating EFPIA companies, Boehringer Ingelheim GmbH, Novartis AG (NYSE:NVS; SWX:NOVN), AstraZeneca plc (LSE:AZN; NYSE:AZN), Pfizer Inc. (NYSE:PFE) and Roche (SWX:ROG) participated in 15 or more projects each.

 

Project title

 

EFPIA Participants

 

Contribution (millions)

 

Duration (years)

 

EFPIA

 

IMI

 

[1] Improve predictivity and minimization strategies of immunogenicity for biotherapeutics in man

 

12 companies: AstraZeneca; Bayer Healthcare, a subsidiary of Bayer AG (Xetra:BAY); Boehringer Ingelheim; Genzyme Corp. (NASDAQ:GENZ);
H. Lundbeck A/S (CSE:LUN); Merck & Co. Inc. (NYSE:MRK); Merck Serono S.A., a subsidiary of Merck KGaA (Xetra:MRK); Novartis; Novo Nordisk A/S (CSE:NVO; NYSE:NVO); Pfizer; Roche; UCB Group (Euronext:UCB)

 

13 ($20)

 

~ 9 ($13.9)

 

5

 

[2] Nongenotoxic carcinogenesis: identification of early markers and molecular classification of tumors

 

8 companies: Bayer Healthcare; Boehringer Ingelheim; Lundbeck; Novartis; Novo Nordisk; Pfizer; Solvay S.A. (Euronext:SOLB); UCB

 

12.5 ($19.3)

 

~ 9 ($13.9)

 

5

 

[3] Development of expert systems for in silico toxicity prediction

 

10 companies: AstraZeneca; Bayer Healthcare; Boehringer Ingelheim; Esteve S.A.; GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Lundbeck; Novartis; Pfizer; Roche; UCB

 

5
($7.7)

 

~ 4 ($6.2)

 

5

 

[4] Improved predictivity of nonclinical safety evaluation

 

10 companies: Bayer Healthcare; Boehringer Ingelheim; Merck Serono; Novartis; Orion Pharma, a subsidary of Orion Corp. (HSE:ORNAV; HSE:ORNBV); Roche; sanofi-aventis Group (Euronext:SAN; NYSE:SNY); Servier; Solvay; UCB

 

10 ($15.4)

 

~ 7 ($10.8)

 

3

 

[5] Qualification of translational safety biomarkers from nonclinical to early clinical studies

 

12 companies: Laboratorios Almirall S.A.; Amgen Inc. (NASDAQ:AMGN); AstraZeneca; Boehringer Ingelheim; Eli Lilly and Co. (NYSE:LLY); GlaxoSmithKline; Johnson & Johnson (NYSE:JNJ); Merck Serono; Novartis; Pfizer; Roche; Solvay

 

21 ($32.4)

 

~ 15 ($23.1)

 

5

 

[6] Improving and strengthening the monitoring of the benefit and risk of medicines marketed in the EU

 

15 companies: Amgen; AstraZeneca; Bayer Healthcare; Boehringer Ingelheim; Eli Lilly; Genzyme; GlaxoSmithKline; Lundbeck; Merck Serono; Novartis; Novo Nordisk; Pfizer; Roche; sanofi-aventis; Sigma-Tau S.p.A.

 

15 ($23.1)

 

~ 11 ($17)

 

5

 

[7] Islet cell research: improving b-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes

 

11 companies: Amgen; AstraZeneca; Boehringer Ingelheim; Eli Lilly; Merck; Novartis; Novo Nordisk; Roche; sanofi-aventis; Servier; Solvay

 

10 ($15.4)

 

~ 7 ($10.8)

 

5

 

[8] Surrogate markers for micro- and macrovascular hard endpoints to shorten clinical trials on diabetes

 

7 companies: Boehringer Ingelheim; Eli Lilly; Novo Nordisk; Laboratoires Pierre Fabre S.A.; Roche; Servier; Solvay

 

20 ($30.8)

 

~ 14 ($21.6)

 

5

 

[9] Pain research: innovative preclinical and clinical rapprochement to produce biomarkers for safer and more effective treatments

 

12 companies: AstraZeneca; Boehringer Ingelheim; Eli Lilly; Esteve; GlaxoSmithKline; Merck; Orion Pharma; Pfizer; Pierre Fabre; sanofi-aventis; UCB; Wyeth (NYSE:WYE)

 

7.5 ($11.6)

 

~ 5 ($7.7)

 

5

 

[10] New tools for the development of new therapies in psychiatric disorders

 

13 companies: AstraZeneca; Eli Lilly; GlaxoSmithKline; Johnson & Johnson; Lundbeck; Novartis; Orion Pharma; Pfizer; Pierre Fabre; Roche; Servier; Solvay; Wyeth

 

10 ($15.4)

 

~ 7 ($10.8)

 

5

 

[11] Neurodegenerative disorders: bridging the preclinical-clinical divide

 

14 companies: AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Johnson & Johnson; Eli Lilly; Lundbeck; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche; Servier; Solvay; UCB

 

7.5 ($11.6)

 

~ 5 ($7.7)

 

5

 

[12] Understanding severe asthma: the fundamental bottleneck to advancing new medicines for the syndrome

 

10 companies: Almirall; AstraZeneca; Boehringer Ingelheim; Chiesi Farmaceutici S.p.A.; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche; UCB

 

12.5 ($19.3)

 

~ 9 ($13.9)

 

5

 

[13] Chronic obstructive pulmonary disease patient-recorded outcomes: a major bottleneck to understanding patient and economic benefits of new therapies

 

9 companies: Almirall; AstraZeneca; Boehringer Ingelheim; Chiesi; GlaxoSmithKline; Merck; Novartis; Pfizer; UCB

 

10
($15.4)

 

~ 7 ($10.8)

 

6

 

[14] Establishment of a network to facilitate and coordinate European training and education relevant for stakeholders of medicines R&D

 

24 companies: Almirall; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Chiesi; Eli Lilly; Esteve; Genzyme; GlaxoSmithKline; Johnson & Johnson; Lundbeck; Merck; Merck Serono; Novartis; Novo Nordisk; Orion; Pierre Fabre; Pfizer; Roche; sanofi-aventis; Servier; Sigma-Tau; UCB

 

5
($7.7)

 

~ 4 ($6.2)

 

7

 

[15] IMI safety sciences for medicines training program

 

24 companies: Almirall; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Chiesi; Eli Lilly; Esteve; Genzyme; GlaxoSmithKline; Johnson & Johnson; Lundbeck; Merck; Merck Serono; Novartis; Novo Nordisk; Orion; Pierre Fabre; Pfizer; Roche; sanofi-aventis; Servier; Sigma-Tau; UCB

 

3
($4.6)

 

~ 2 ($3.1)

 

5

 

[16] IMI pharmaceutical medicine training program

 

24 companies: Almirall; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Chiesi; Eli Lilly; Esteve; Genzyme; GlaxoSmithKline; Johnson & Johnson; Lundbeck; Merck; Merck Serono; Novartis; Novo Nordisk; Orion; Pierre Fabre; Pfizer; Roche; sanofi-aventis; Servier; Sigma-Tau; UCB

 

4
($6.2)

 

~ 3 ($4.6)

 

5

 

[17] IMI integrated medicines development course program for nonspecialists

 

24 companies: Almirall; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Chiesi; Eli Lilly; Esteve; Genzyme; GlaxoSmithKline; Johnson & Johnson; Lundbeck; Merck; Merck Serono; Novartis; Novo Nordisk; Orion; Pierre Fabre; Pfizer; Roche; sanofi-aventis; Servier; Sigma-Tau; UCB

 

3
($4.6)

 

~ 2 ($3.1)

 

5

 

[18] IMI pharmacovigilance training program

 

24 companies: Almirall; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Chiesi; Eli Lilly; Esteve; Genzyme; GlaxoSmithKline; Johnson & Johnson; Lundbeck; Merck; Merck Serono; Novartis; Novo Nordisk; Orion; Pierre Fabre; Pfizer; Roche; sanofi-aventis; Servier; Sigma-Tau; UCB

 

3.5 ($5.4)

 

~ 3 ($4.6)

 

5